PE Ratio
52.07
₹2,013.20 -35.80 (-1.75%)
As on October 12, 2026
199.47%
1 Y CAGR
4,853
CR
Market Cap
Company profile
Novartis India Limited, an Indian healthcare enterprise, provides a diverse range of pharmaceutical solutions. Its offerings include branded medications for conditions related to bone and pain management, calcium supplementation, women's health (gynecology), and neurological disorders. Furthermore, the company supplies generic drugs specifically for gynecological issues, anti-tuberculosis treatments, and anti-infective applications. Notable branded products within its portfolio comprise Tegrital and Exelon for central nervous system disorders, Voveran for pain and inflammation relief, and specialized transplantation/immunology drugs like Simulect, Certican, Myfortic, and Sandimmun Neoral. Established in 1947 and headquartered in Mumbai, India, Novartis India Limited operates as a subsidiary of Novartis AG.
Price Chart
Fundamentals - Company Valuation
PB Ratio
0.24
Dividend Yield
1.47%
Sector PE
47.63
Sector ROE
11.70%
Sector Dividend Yield
0.46%
Financials
LIVE DATA FEED
Total Revenue (YTD)
₹3.5KCAGR 5-Year
-2.98%Peers & Comparison
SUNPHARMA
Sun Pharmaceutical Industries Ltd
Market cap: ₹4,41,477.63 Cr
DIVISLAB
Divi's Laboratories Ltd
Market cap: ₹2,41,576.41 Cr
TORNTPHARM
Torrent Pharmaceuticals Ltd
Market cap: ₹1,82,576.57 Cr
Missed the last rally? Don’t miss the next
Looking for AI-researched technical positive stocks?
Our AI-powered Analytical Portal finds the strongest technical positive stocks with actionable Buy & Sell opportunities.
Corporate Actions
Still Thinking? Not sure which stocks are right for you?
We help investors understand what to buy, when to buy, and why it makes sense for them.
customersupport@jarvisinvest.com
New Customers (Enquiry): +91 7208809638
Mon - Sat | 10:00 AM - 07:00 PM (Sunday Closed)
